Marshall Wace
CRDL

Marshall Wace’s Cardiol Therapeutics CRDL Stock Holding History

Marshall Wace’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-151,517
Closed -$144K – 3274
2025
Q4 		$144K Sell
151,517
-392,800
-72% -$411K ﹤0.01% 2658
2025
Q3 		$582K Buy
+544,317
New +$660K ﹤0.01% 2170
2025
Q1 		– Sell
-13,193
Closed -$16.9K – 2695
2024
Q4 		$16.9K Buy
+13,193
New +$22.2K ﹤0.01% 2514

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace's CRDL Position: Q1 2026 in Review

Marshall Wace sold out of Cardiol Therapeutics (CRDL) in Q1 2026, closing a stake of 151,517 shares — an estimated $144K sold.

Marshall Wace first reported a position in CRDL in Q4 2024 and held it in 3 quarters. The position peaked at $582K in Q3 2025. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

  • Marshall Wace reported no remaining Cardiol Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Marshall Wace sold 151,517 Cardiol Therapeutics shares in Q1 2026, an estimated $144K.
  • Marshall Wace first reported a position in Cardiol Therapeutics in Q4 2024 and held it in 3 quarters.
  • Marshall Wace's Cardiol Therapeutics position peaked at $582K in Q3 2025.
  • 47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.